NovoCure Ltd (NASDAQ: NVCR) kicked off on Tuesday, down -4.73% from the previous trading day, before settling in for the closing price of $15.63. Over the past 52 weeks, NVCR has traded in a range of $10.87-$24.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 17.16%. While this was happening, its average annual earnings per share was recorded 29.89%. With a float of $97.51 million, this company’s outstanding shares have now reached $107.08 million.
Let’s determine the extent of company efficiency that accounts for 1453 employees. In terms of profitability, gross margin is 75.82%, operating margin of -33.65%, and the pretax margin is -25.66%.
NovoCure Ltd (NVCR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 9.89%, while institutional ownership is 85.90%. The most recent insider transaction that took place on Aug 02 ’24, was worth 13,857. In this transaction Chief Financial Officer of this company sold 688 shares at a rate of $20.14, taking the stock ownership to the 219,179 shares. Before that another transaction happened on Jun 04 ’24, when Company’s Director sold 964 for $23.89, making the entire transaction worth $23,033. This insider now owns 164,833 shares in total.
NovoCure Ltd (NVCR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 29.89% per share during the next fiscal year.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Take a look at NovoCure Ltd’s (NVCR) current performance indicators. Last quarter, stock had a quick ratio of 6.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Looking closely at NovoCure Ltd (NASDAQ: NVCR), its last 5-days average volume was 0.66 million, which is a drop from its year-to-date volume of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 7.09%. Additionally, its Average True Range was 1.00.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 2.38%, which indicates a significant decrease from 5.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.34% in the past 14 days, which was lower than the 69.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.20, while its 200-day Moving Average is $16.67. However, in the short run, NovoCure Ltd’s stock first resistance to watch stands at $15.38. Second resistance stands at $15.88. The third major resistance level sits at $16.24. If the price goes on to break the first support level at $14.52, it is likely to go to the next support level at $14.16. Now, if the price goes above the second support level, the third support stands at $13.66.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
The company with the Market Capitalisation of 1.61 billion has total of 107,611K Shares Outstanding. Its annual sales at the moment are 509,340 K in contrast with the sum of -207,040 K annual income. Company’s last quarter sales were recorded 150,360 K and last quarter income was -33,380 K.
